Core Viewpoint - Kang Le Wei Zhi (920575) experienced a trading halt today, reaching a daily increase of 29.90% with a turnover rate of 18.70% and a total transaction amount of 402 million yuan, despite a net sell-off of 3.1751 million yuan from brokerage seats [2] Trading Activity Summary - The stock was listed on the North Exchange due to its daily price fluctuation limit being reached, with a total net sell of 3.1751 million yuan from brokerage seats [2] - According to statistics from Securities Times·Data Treasure, the top five brokerage seats accounted for a total transaction amount of 122 million yuan, with a buying amount of 59.34 million yuan and a selling amount of 62.51 million yuan, resulting in a net sell of 3.1751 million yuan [2] - The largest buying brokerage was Yongxing Securities Co., Ltd. Ningbo Heyuan Road Securities Office, with a buying amount of 17.685 million yuan, while the largest selling brokerage was Guojin Securities Co., Ltd. Chengdu Wucheng Street Securities Office, with a selling amount of 27.5929 million yuan [2] Detailed Brokerage Activity - The top five buying brokerages and their respective amounts are as follows: - 1st: Yongxing Securities Co., Ltd. Ningbo Heyuan Road Securities Office - 17.685 million yuan - 2nd: Dongfang Caifu Securities Co., Ltd. Lhasa East Ring Road Second Securities Office - 10.7875 million yuan - 3rd: Dongfang Securities Co., Ltd. Kunming Bailong Road Securities Office - 9.9627 million yuan - 4th: Dongwu Securities Co., Ltd. Suzhou Xiangcheng Cailian Road Securities Office - 8.4611 million yuan - 5th: Huazheng Securities Co., Ltd. Zhengzhou Longhai Road Securities Office - 8.2259 million yuan [2] - The top five selling brokerages and their respective amounts are as follows: - 1st: Guojin Securities Co., Ltd. Chengdu Wucheng Street Securities Office - 27.5929 million yuan - 2nd: Guotou Securities Co., Ltd. Guangzhou Dongfeng Middle Road Securities Office - 0.084 million yuan - 3rd: Dongfang Caifu Securities Co., Ltd. Lhasa East Ring Road Second Securities Office - 11.3147 million yuan - 4th: Guoxin Securities Co., Ltd. Shenzhen Hongling Middle Road Securities Office - 5.9266 million yuan - 5th: Guojin Securities Co., Ltd. Shenzhen Branch - 4.4918 million yuan [2]

为满足公司日常生产经营及业务开展的需要,推动公司持续发展,公司控股 股东天狼星控股集团有限公司(以下简称"天狼星集团")为公司与上海斯丹姆 医药开发有限责任公司前期签署的临床试验相关合同项下 41,156,462.22 元费用 提供连带责任保证担保。 天狼星集团、公司实际控制人陶涛先生及其配偶为公司分别与广州金曼利医 药科技有限公司、金堤利醫藥(香港)有限公司及广州金域医学检验中心有限公 司前期签署的临床试验相关合同项下合计 32,118,245.80 元费用提供连带责任保 证担保。 二、关联方基本情况 中信证券股份有限公司 关于北京康乐卫士生物技术股份有限公司 接受关联方担保暨关联交易事项的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐机构"）作为北京康乐 卫士生物技术股份有限公司(以下简称"康乐卫士"、"公司")持续督导的保荐机 构,根据《证券发行上市保荐业务管理办法》《北京证券交易所上市公司持续监 管办法(试行)》《北京证券交易所证券发行上市保荐业务管理细则》《北京证券 交易所股票上市规则》等相关法律、法规和规范性文件的规定,对康乐卫士接受 关联方担保暨关联交易事项进行了核查,具体如下: ...

证券代码：920575 证券简称：康乐卫士 公告编号：2026-002 北京康乐卫士生物技术股份有限公司 关于接受关联方担保暨关联交易公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、关联交易概述 （一）关联交易概述 为满足北京康乐卫士生物技术股份有限公司（以下简称"公司"）日常生产 经营及业务开展的需要，推动公司持续发展，公司控股股东天狼星控股集团有限 公司（以下简称"天狼星集团"）为公司与上海斯丹姆医药开发有限责任公司前 期签署的临床试验相关合同项下 41,156,462.22 元费用提供连带责任保证担保。 天狼星集团、公司实际控制人陶涛先生及其配偶为公司分别与广州金墁利医 药科技有限公司、金墁利醫藥（香港）有限公司及广州金域医学检验中心有限公 司前期签署的临床试验相关合同项下合计 32,118,245.80 元费用提供连带责任保 证担保。 （二）决策与审议程序 公司于 2026 年 1 月 12 日召开了第五届董事会 2026 年第一次独立董事专门 会议、第五届董事会第十五次会议，审议通过 ...

公司股东天狼星控股集团有限公司质押 5,500,000 股，占公司总股本 1.96%。 在本次质押的股份中，5,500,000 股为有限售条件股份，0 股为无限售条件股份。 质押期限为 2026 年 1 月 12 日起至业务结清止。质押股份用于为公司银行授信提 供担保，质押权人为兴业银行股份有限公司北京大兴支行，质押权人与质押股东 不存在关联关系。质押股份已在中国结算办理质押登记。 证券代码：920575 证券简称：康乐卫士 公告编号：2026-005 北京康乐卫士生物技术股份有限公司 股权质押的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、股权质押概述 （一）基本情况 公司股东天狼星控股集团有限公司质押 10,000,000 股，占公司总股本 3.56%。 在本次质押的股份中，10,000,000 股为有限售条件股份，0 股为无限售条件股份。 质押期限为 2026 年 1 月 8 日起至业务结清止。质押股份用于为公司银行授信提 供担保，质押权人为北京银行股份有限公司北京经济技术开发区分行， ...

证券代码：920575 证券简称：康乐卫士 公告编号：2026-003 北京康乐卫士生物技术股份有限公司 第五届董事会第十五次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2026 年 1 月 12 日 2.会议召开地点：公司会议室 3.会议召开方式：现场与通讯相结合的方式 4.发出董事会会议通知的时间和方式：2026 年 1 月 8 日以邮件和电话方式发 出 会议应出席董事 9 人，出席和授权出席董事 9 人。 二、议案审议情况 （一）审议通过《关于接受关联方担保暨关联交易的议案》 1.议案内容： 为满足北京康乐卫士生物技术股份有限公司（以下简称"公司"）日常生产 经营及业务开展的需要，推动公司持续发展，公司控股股东天狼星控股集团有限 公司（以下简称"天狼星集团"）为公司与上海斯丹姆医药开发有限责任公司前 期签署的临床试验相关合同项下 41,156,462.22 元费用提供连带责任保证担保。 天狼星集团、公司实际控制人陶涛先 ...

每经讯，2026年1月13日，北交所上市公司康乐卫士（920575，收盘价：11.99元）登上龙虎榜，交易方式是连续竞价，披露原因 是当日收盘价涨幅达到29.90%，成交数量3511.98万股，成交金额4.02亿元。买一席位为甬兴证券有限公司宁波和源路证券营业 部，买入1768.5万元；卖一席位为国金证券股份有限公司成都武成大街证券营业部，卖出2759.29万元。 | | 2026-01-13康乐卫士 (920575) 龙虎榜 | | | | --- | --- | --- | --- | | 序号 | 交易营业部名称 | 买入金额(元) | 卖出金额(元) | | न्द्र ग | 用兴证券有限公司宁波和源路证券营业部 | 17684998.21 | 0 | | 址2 | 东方财富证券股份有限公司拉萨东环路第二证券营业部 | 10787525 | 11314658.06 | | ग्रें3 | 东方证券股份有限公司昆明白龙路证券营业部 | 9962715.23 | 0 | | 买4 | 东吴证券股份有限公司苏州相城采莲路证券营业部 | 8461071.27 | 0 | | ન્નેર | 华安证券股份有 ...

Core Viewpoint - The biopharmaceutical sector experienced a rise of 1.15% on January 13, with Kanglaweishi leading the gains, while the overall market indices, Shanghai Composite and Shenzhen Component, saw declines of 0.64% and 1.37% respectively [1]. Group 1: Biopharmaceutical Sector Performance - Kanglaweishi (code: 920575) closed at 11.99, up 29.90% with a trading volume of 351,200 shares and a transaction value of 402 million yuan [1]. - Rongchang Biotech (code: 688331) closed at 114.46, up 20.00% with a trading volume of 212,200 shares and a transaction value of 2.369 billion yuan [1]. - Yian Protein (code: 688137) closed at 49.60, up 15.43% with a trading volume of 58,100 shares and a transaction value of 291 million yuan [1]. - The overall biopharmaceutical sector saw a net inflow of 399 million yuan from institutional investors, while retail investors experienced a net outflow of 336 million yuan [2]. Group 2: Individual Stock Flows - Kanglaweishi had a net inflow of 191 million yuan from institutional investors, accounting for 47.65% of its trading volume [3]. - Anke Biotech (code: 300009) had a net inflow of 92 million yuan from institutional investors, but a net outflow of 82 million yuan from retail investors [3]. - The stock with the highest retail outflow was Bohui Innovation (code: 300318), which saw a net outflow of 54 million yuan from retail investors [3].

证券代码：920575 证券简称：康乐卫士 公告编号：2026-001 北京康乐卫士生物技术股份有限公司 关于公司银行授信暨关联交易公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、关联交易概述 （一）关联交易概述 在上述授权期限内，融资授信额度可循环使用，在不超过融资授信额度及担 保额度的情况下，上述申请事项具体实施无需再逐项提请董事会及股东会审批。 公司将按照相关规定，根据上述融资担保事项实际情况和协议内容及时履行信息 披露义务。 1、为满足业务发展需要，北京康乐卫士生物技术股份有限公司（以下简称 "公司"）向北京银行申请不超过壹亿元（含壹亿元）综合授信额度，用于贷款、 承兑汇票、保函等业务融通使用，期限肆年，担保方式为由公司控股股东天狼星 控股集团有限公司（以下简称"天狼星集团"），公司实际控制人陶涛夫妇，公司 时任董事长、法定代表人郝春利夫妇，公司时任董事、总经理刘永江夫妇提供连 带责任保证担保。根据最终签署的授信合同，上述银行授信最高授信额度为捌仟 万元整，担保方式为由公司控股股东天狼 ...

Market Overview - In 2025, the A-share market experienced a structural "small bull" market, with 4,110 out of 5,176 stocks showing positive growth, and 523 stocks rising over 100% [1] - However, 40 stocks fell over 30%, with 7 stocks declining more than 40% [1] Worst Performing Stocks - The largest decline was seen in Shijing Technology, which dropped 50.99% in 2025, primarily due to a significant decrease in completed orders after entering the photovoltaic sector [3] - Kangle Weishi ranked second with a decline of 49.97%, continuing to face losses since 2013, with a net profit loss of 2.29 billion yuan in the first three quarters of 2025 [3][4] - Longda Meishi experienced a 48.11% drop, affected by a prolonged downturn in the pig cycle and intensified competition in the prepared food sector [3] Financial Performance - Kangle Weishi reported a revenue of 1.2763 million yuan in the first three quarters of 2025, a year-on-year increase of 106.53%, but still faced a net profit loss of 2.29 billion yuan [4] - The food and beverage sector saw a 9.69% decline in 2025, marking its fifth consecutive year of losses, with a cumulative drop of over 50% since the peak in 2021 [8][10] Industry Trends - The pharmaceutical and biotechnology sector showed signs of recovery in 2025, with an 11.94% increase, ending a four-year downtrend [10] - The food and beverage sector is expected to benefit from macro policies aimed at boosting domestic demand, with potential recovery in the white liquor and pre-processed food segments [10][11]

Group 1 - The stock of Kang Le Wei Shi (920575.BJ) closed at 8.27 yuan, with a decline of 4.83%, currently in a state of breaking issue [1] - Kang Le Wei Shi was listed on the Beijing Stock Exchange on March 15, 2023, with an initial offering price of 42.00 yuan, and the stock closed at 35.52 yuan on its first day, a drop of 15.43% [1] - The company issued 7,000,000 shares (excluding the overallotment option) and 8,050,000 shares (if the overallotment option is fully exercised) [1] Group 2 - The total amount of funds raised by Kang Le Wei Shi before the exercise of the overallotment option was 29,400,000 yuan, with a net amount of 26,662,410 yuan after deducting issuance costs of 2,737,590 yuan (excluding VAT) [1] - The net amount raised was 3,337,590 yuan less than the original plan of 30,000,000 yuan, which was intended for HPV vaccine research and the construction of a production base in Kunming [1] - The total issuance costs were 2,737,590 yuan (before the exercise of the overallotment option) and 3,008,020 yuan (if the overallotment option is fully exercised) [2] Group 3 - On May 17, 2023, Kang Le Wei Shi announced a dividend plan of 10 shares for every 10 shares, with the ex-dividend date set for May 26, 2023 [3]